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Synaptic alterationS in rett Syndrome
In agreement with this hypothesis, direct evidences supporting 
the involvement of MeCP2 in the regulation of synaptic connec-
tivity are now available. First of all, postmortem analyses of the 
brain of RS patients revealed structural abnormalities of synapses 
such as decreased number of dendritic spines in discrete cortical 
areas (Belichenko et al., 1994). A more recent quantitative analysis 
showed that both secondary and tertiary apical dendrites of pyrami-
dal neurons in the CA1 area of the hippocampus of RS patients 
displayed less dendritic spines than unaffected individuals, with no 
significant correlation between age and spine density (Chapleau 
et al., 2009). Interestingly, autoradiographic analyses in the cor-
tex and in the basal ganglia of patients revealed that the density 
of NMDA, AMPA, and GABA receptors was significantly altered 
(Johnston et al., 2005), a result indicating that RS is associated with 
abnormalities in the expression of molecules that are crucial for 
both excitatory and inhibitory synaptic transmission.
Similarly to RS patients, a number of recent studies pointed out 
morphological, functional and molecular alterations of synapses 
in neurons of different mice models of the disease (see Table 1). 
Hippocampal neurons cultured from MeCP2-KO mouse brains 
showed a decreased frequency of spontaneous excitatory synap-
tic transmission (EPSCs, Nelson et al., 2006). Moreover, autaptic 
hippocampal cultures from MeCP2-KO mice displayed a reduc-
tion in both frequency and amplitude of action-potential evoked 
EPSCs, whereas neurons from MeCP2Tg1 mice, in which wild-type 
(WT) human MeCP2 is approximately two-fold higher than in 
normal  animals  (Collins  et  al.,  2004),  showed  an  increase  of 
introduction
Loss-of-function mutations in the X-linked methyl-CpG binding 
protein 2 (Mecp2) gene, a transcriptional regulator that acts through 
epigenetic mechanisms on chromatin structure, cause the 95% of 
Rett’s syndrome (RS; MIM312750) cases, a severe neurological 
disorder that affects about 1:10000 girls worldwide (Amir et al., 
1999). Importantly, alterations in MeCP2 expression are associated 
to several other neurological conditions such as Angelman-like syn-
drome, motor deficits, learning disabilities, seizures, bipolar disease, 
juvenile-onset schizophrenia, autism-like features, psychosis, etc 
(Chahrour and Zoghbi, 2007).
Interestingly, the discovery that target mutation of MeCP2 
in the central nervous system may produce a phenotype similar 
to the whole body mutation have indicated that impairment of 
MeCP2 function in the brain is crucial for the pathogenesis of 
the disease (Chen et al., 2001; Guy et al., 2001). Despite the severe 
neurological abnormalities, the brain of RS patients and of animal 
models does not show obvious anatomical alterations apart from 
a decreased weight and volume of about 12–34% (Chahrour and 
Zoghbi, 2007). Such changes are not generalized but more pro-
nounced in specific brain areas (Reiss et al., 1993; Subramaniam 
et al., 1997; Kishi and Macklis, 2004; Armstrong, 2005; Stearns 
et al., 2007). Importantly, RS brain does not show obvious signs 
of neurodegeneration, atrophy, gliosis, demyelination, or neuronal 
migration defects (Jellinger et al., 1988; Reiss et al., 1993) suggest-
ing that neurological symptoms may primarily stem from subtle 
defects of subcellular compartments such as dendrites, axons, or 
synaptic structures.
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these   parameters (Chao et al., 2007). In line with these   functional 
changes, the number of immunopositive puncta for the excitatory 
synapse molecules PSD-95 and vesicular glutamate transporter-1 
(VGLUT1) was found to be decreased in MeCP2-KO cultures 
brains while it was increased in cultures deriving from MeCP2Tg1 
mice. Indeed, recent analyses showed that overexpression of both 
WT and mutated forms (MeCP2R106W and MeCP2T158M) of MeCP2 
proteins in organotypic hippocampal slices caused a reduction of 
dendritic spine density in CA1 pyramidal neurons 48 h after viral 
infection (Zhou et al., 2006; Chapleau et al., 2009). However, the 
overexpression of the WT form of the protein led only to a transient 
alteration in dendritic spine number that returned normal after 
96 h. Accordingly, a previous study had shown that overexpression 
of MeCP2 in hippocampal slices did not affect dendritic spine 
density 5 days after transfection but it altered spine morphology 
leading to an increased proportion of longer and thinner dendritic 
spines (Zhou et al., 2006). Moreover, knockdown of endogenous 
MeCP2 with a specific small hairpin interference RNA induced 
a decrease in spine density appearing after 96 h of expression, 
and produced a specific loss of mature-shaped dendritic spines 
(Chapleau et al., 2009). In contrast with this study, previous data 
had indicated that 5-days-long down-regulation of MePC2 expres-
sion did not affect dendritic spine density but instead decreased 
neuronal dendritic complexity (Zhou et al., 2006). Altogether, 
these studies indicate that MeCP2 expression may contribute to 
the normal density and morphology of dendritic spines in CA1 
pyramidal neurons of the hippocampus.
Importantly, synaptic alterations produced by the manipula-
tion of MeCP2 expression have been described in the brain of 
different mouse models of RS (see Table 2), further indicating 
that these animals are suitable to investigate the neurobiologi-
cal bases of the disease. Indeed, newly generated neurons in the 
hippocampal dentate gyrus of 8 weeks old MeCP2Jae-KO male 
mice showed altered density and distribution of dendritic spines 
(Smrt et al., 2007). Moreover, recent studies reported that in the 
hippocampus and the primary motor (M1) cortex of both young 
and adult MeCP2Bird-KO and MeCP2Jae-KO male mice there is a 
decrease of dendritic spine density (Fukuda et al., 2005; Belichenko 
et al., 2009b; Tropea et al., 2009). Interestingly, neural circuits of 
MeCP2Bird-KO mice seem to be more severely affected as they 
also showed abnormalities in presynaptic structures reported as 
defects of axonal fasciculation in the M1 cortex. Finally, it was 
found that synaptic defects may appear early during   development 
as a consequence of altered levels of MeCP2 expression. Indeed, 
VGLUT1 immunolabeling intensity is reduced in 2 weeks old 
MeCP2Bird-KO mice and increased in MeCP2Tg1 mutants. In con-
trast, these immunolabeling changes appeared to be milder at 
5 weeks of age (Chao et al., 2007). Also, 6–7 months old MeCP2Bird 
heterozygous female mice displayed a decrease of dendritic spine 
density in layer V pyramidal neurons of the M1 cortex (Belichenko 
et al., 2009a). As observed in RS girls, patients, female MeCP2+/− 
mice show mosaic expression of mutant and wild-type Mecp2 
alleles caused by the random inactivation of one X-linked Mecp2 
allele (Chahrour and Zoghbi, 2007). The density of dendritic 
spines in neurons expressing MeCP2 seemed to be more severely 
affected than in MeCP2-negative ones, thus indicating both a 
cell autonomous and a non-cell autonomous effect of MeCP2 
deletion in the organization of synaptic structures (Belichenko 
et al., 2009a).
Several  electrophysiological  properties  of  synaptic  connec-
tions were also found abnormal in MeCP2 mutants (see Table 2). 
Whole-cell patch clamp recordings of layer V pyramidal neurons 
in the primary somatosensory (S1) cortex revealed a reduction of 
both spontaneous EPSCs and spontaneous action potential firing 
in MeCP2-KO male mice (Dani et al., 2005; Chang et al., 2006; 
Tropea et al., 2009). Intriguingly, the drive of excitatory inputs 
on layer V cortical neuron was reduced in MeCP2-KO animals 
whereas the total inhibitory input was enhanced, indicating that 
the absence of MeCP2 produces a shift of the homeostatic bal-
ance between excitation and inhibition in favor of inhibition (Dani 
et al., 2005). In addition, using quadruple whole-cell recordings 
on cortical slices obtained from 4 weeks old MeCP2-KO mice, it 
has been recently reported that excitatory synaptic connectivity 
between layer V thick-tufted pyramidal neurons is reduced (Dani 
and Nelson, 2009). In agreement with these functional impair-
ments, immunofluorescence signal of the synaptic scaffolding pro-
tein PSD-95 is reduced in layer V of the M1 cortex of MeCP2Jae 
mutants compared with WT mice (Tropea et al., 2009). Significative 
alterations of neurosecretory processes have also been reported in 
association with MeCP2 deletion (Wang et al., 2006). This study 
indicated that cultured nodose ganglia neurons from P0 and P35 
KO-mice show an increased secretion of BDNF in basal condi-
tions compared with WT neurons. Moreover, these authors used 
an adrenal medulla slice preparation to show that the size of the 
ready releasable granule pool is increased in MeCP2-KO chroma-
ffin cells. These data suggest that alterations of the level of both 
Table 1 | Types of MeCP2 mouse mutants tested for defects in synaptic connectivity and plasticity.
Mouse model  Mutation type  Mutation result  Mutant life span
MeCP2Jae (Chen et al., 2001)  Deletion of exon 3  Loss of function  Maley/−: 10–12 weeks;  
  (homologous recombination)    Female+/−: normal 
MeCP2Bird (Guy et al., 2001)  Deletion of exons 2 and 3  Loss of function  Maley/−: 7–8 weeks;  
  (homologous recombination)    Female+/−: normal
MeCP2308 (Shahbazian et al., 2002)  Stop codon after 308 codon  Truncated MeCP2 protein  Maley/308: 10% about 10 months;  
  (homologous recombination)    90% at least 1 year
MeCP2Tg1 (Collins et al., 2004)  Insertion of PAC clone containing MeCP2  MeCP2 overexpression  Male: 30% between 20 weeks 
  under endogenous human promoter    to 1 year; 70% normalFrontiers in Synaptic Neuroscience  www.frontiersin.org  August 2010  | Volume 2  | Article 28  |  3
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impaired. Long-term potentiation (LTP) of the Schaffer’s collateral-
CA1 pathway (Sc-CA1) in the CA1 area of the hippocampus rep-
resents an activity-dependent increase of the strength of synaptic 
transmission that is thought to underlie many forms of explicit 
memory formation. Acute hippocampal slices from MeCP2-KO 
male mice (age >6 weeks) showed a clear reduction in the magni-
tude of LTP induced by high-frequency stimulation, an impairment 
that becomes visible minutes after the tetanic stimulation. However, 
LTP evoked by theta-burst stimulation, which reproduces a physi-
ological pattern of neuronal stimulation, outlined synaptic defects 
that were present only in the maintenance but not in the induction 
phase of potentiation. Thus, these experiments indicate that the 
neuronal machinery underlying LTP is not entirely impaired by 
the loss of MeCP2 but it could affect the stimulus threshold for 
the induction/maintenance phases of synaptic potentiation (Asaka 
et al., 2006). Interestingly, LTP induction and maintenance in hip-
pocampal slices from 3 to 5 weeks old KO mice appeared normal 
suggesting that synaptic plasticity in this area might be preserved 
at early postnatal stages. Similarly, Asaka et al. (2006) demonstrated 
that long-term depression (LTD) at hippocampal Sc-CA1 synapses, 
another form of learning-related synaptic plasticity, is abolished in 
KO male mice of age >6 weeks while no alterations were observed 
in 3–5 weeks old mutants in comparison with age-matched WT 
mice. Also short-term plasticity is affected in the hippocampus 
of MeCP2 mutants. Indeed, the study of presynaptic functions 
tested by paired-pulse facilitation (PPF) analysis revealed altera-
tions in >6 weeks old animals, but not in younger MeCP2-KO male 
mice (Asaka et al., 2006). These electrophysiological data came 
with the intriguing observation that the molecular composition 
of the NMDA type of glutamate receptor (NMDAR) is abnormal 
in symptomatic KO mice (Table 2). Mutant animals displayed an 
increased expression of NR2B subunit and a decreased expression 
of NR2A subunit, without changes in the total amount of NMDARs 
(Asaka et al., 2006). These data indicate that the loss of MeCP2 may 
affect the normal shift from NR2B to NR2A subunit expression 
occurring during postnatal development, a molecular change that 
is important for specifying the biophysical and pharmacological 
properties of excitatory synapses in the adult brain. Finally, given 
that NMDARs are crucially involved in synaptic plasticity, these 
authors suggested that such defect in NMDARs expression at syn-
apses might underlie the deficits in long-term hippocampal plastic-
ity showed by symptomatic MeCP2-KO mice.
Likewise, male mice expressing a truncated form of MeCP2 
obtained by positioning a premature stop sequence after 308 codon 
(MeCP2308) display impairments in synaptic plasticity (Table 2). 
These mutants show a reduction of both LTP and LTD at Sc-CA1 
synapses in the hippocampus at 18–22 weeks, a defect in synaptic 
function that was accompanied by a reduction of the length of 
postsynaptic densities at asymmetric contacts (Moretti et al., 2006). 
Moreover, MeCP2308 mice showed increased basal synaptic trans-
mission and decreased PPF at Sc-CA1 pathway suggesting that the 
release probability of synaptic vesicles is enhanced in this model 
(Moretti et al., 2006). In contrast, MeCP2Tg1 mice showed normal 
basal synaptic transmission but displayed an enhancement of both 
PPF and LTP measured in acute hippocampal slices, indicating 
that the effects of MeCP2 overexpression on synaptic plasticity in 
the hippocampus are opposite to those produced by the deletion 
catecholamine and neurotrophin release may have an aversive effect 
on the correct formation of synaptic circuits in MeCP2 mutant 
mice during development (Wang et al., 2006).
So far, the analysis of the organization of synaptic circuits in 
mouse models of RS suggested that MeCP2 may have an impor-
tant role in the formation/maturation of neuronal GABAergic 
connectivity (Table 2). In one study, the authors analyzed inhibi-
tory circuits in the ventro-lateral medulla, an area involved in the 
generation of the respiratory rhythm, of P7 old MeCP2Bird-KO male 
mice (Medrihan et al., 2008). This brain area showed a decrease of 
GABAergic, but not glycinergic, inhibitory neurotransmission at P7. 
Moreover, they found that the expression levels of both mRNA and 
protein of the vesicular-aminobutyric acid transporter (VIAAT) as 
well as of GABAA-α2 receptor subunit is reduced in MeCP2-KO 
mice suggesting that very early molecular and cellular impairments 
of inhibitory circuits may occur in the brain stem of mutant ani-
mals. Moreover, it has been recently shown that GABAergic trans-
mission is selectively altered in two different thalamic nuclei. While 
quantal GABAergic events (mIPSCs) are decreased in neurons of 
the ventral basal complex (VB) in P14-16 MeCP2-KO mice, mIPSCs 
are increased in neurons of the reticular thalamic nucleus (RTN) at 
this age (Zhang et al., 2010), a difference that was detected also in 
P21-23 mutant mice. However, changes in the functional properties 
of inhibitory synapses were found in VB but not in RTN neurons of 
P6 MeCP2-KO mice. Consistently, the VB of MeCP2-KO mice show 
fewer VGAT-positive immunopuncta than WT littermates whereas 
VGAT immunolabeling is increased in the RTN of mutants (Zhang 
et al., 2010). Very recently, we tackled the study of the structural 
organization of GABAergic inhibitory circuits in both the cerebral 
and the cerebellar cortex of MeCP2Jae-KO male mice (Lonetti et al., 
2010). Using electron microscopy and immunogold labeling, we 
showed that at P54 both stellate cell- and basket cell-Purkinje cell 
GABA-positive synapses are more abundant in the cerebellum of 
mutants than in WT animals. In contrast, there was no difference 
between genotypes in the number of GABA-positive synaptic in 
layer III of the S1 cerebral cortex. Taken together, these data suggest 
that MeCP2 may subserve unique functions in diverse inhibitory 
neurons subpopulations throughout the brain.
In summary these studies strongly indicate that RS may alter 
different aspects of neuronal connectivity by affecting the struc-
ture, number, distribution and functional properties of synapses. 
The remainder of this review focuses mainly on the available data 
regarding the effects of different MeCP2 mutations on the expres-
sion of synaptic plasticity.
Synaptic plaSticity in mecp2 mutantS
Synaptic plasticity is particularly high during specific temporal 
windows of development and it is crucial for correct circuit for-
mation. Importantly, these developmental periods coincide with 
the period of emergence of RS symptoms, therefore impairments 
of synaptic plasticity could play an important role in the genesis 
of RS symptoms.
The first demonstration that alteration of MeCP2 expression 
may influence synaptic plasticity came from ex vivo electrophysi-
ological recordings on brain slices. Asaka et al. (2006) showed that in 
the hippocampus of symptomatic MeCP2-KO mice basal synaptic 
transmission was normal whereas long-term synaptic plasticity was Frontiers in Synaptic Neuroscience  www.frontiersin.org  August 2010  | Volume 2  | Article 28  |  5
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  neuronal   activity leads to the release of MeCP2 from bdnf promoter 
region thus   allowing its transcription. In contrast, a more recent study 
suggested that in the hypothalamus of mutants overexpressing MeCP2 
bdnf transcripts are upregulated while in Mecp2-null animals bdnf is 
downregulated, a finding that is in support of the role of MeCP2 as a 
transcriptional activator (Chahrour et al., 2008). Therefore, whether 
the level reduction of BDNF shown by MeCP2-KO mice is a direct 
consequence of the loss of MeCP2 or whether it is an indirect effect 
of the decreased cortical activity shown by these animals is still not 
completely clear.
Other relevant MeCP2 targets are the imprinted genes ube3a 
(ubiquitin protein ligase E3A), gabrb3 (γ-aminobutyric-acid recep-
tor β3) and dlx5 (distal-less homeobox 5) whose expression is altered 
both in RS patients and in MeCP2-KO mice (Horike et al., 2005; 
Makedonski et al., 2005; Samaco et al., 2005). Interestingly, ube3a is 
a gene that is found deregulated in other autism spectrum disorders, 
while dlx5 is involved in forebrain development and neurogenesis 
(Perera et al., 2004) as well as in the differentiation of GABAergic 
interneurons (Stühmer et al., 2002). Recently, gene expression anal-
yses conducted on selected brain regions have pointed out interest-
ing results, supporting the idea that MeCP2 may produce unique 
effects in specific neuronal populations. The study of the olfactory 
system showed that at least 13 different proteins with various func-
tions (e.g., chromatin remodeling, energy metabolism, cell signal-
ing, and neuroprotection) are abnormally expressed in MeCP2-KO 
male mice (Matarazzo and Ronnett, 2004). Microarray analyses in 
the hypothalamus revealed a massive transcriptional deregulation 
(2582 genes) in both MeCP2Tg1 and MeCP2-KO mice. These two 
mouse models largely shared the same misregulated genes strongly 
suggesting that these genes may represent direct targets of MeCP2 
(Chahrour et al., 2008). To validate this hypothesis, these authors 
used chromatin immune-precipitation (Chip) and showed that 
MeCP2 can bind to the promoter region and activate the expres-
sion of genes encoding somatostatin (Sst), opioid receptor kappa 
1 (Oprk1), guanidinoacetate methyltransferase (Gamt), G protein-
regulated inducer of neurite outgrowth 1 (Gprin1). Intriguingly, 
GAMT deficiency has been found in patients showing severe mental 
retardation, absent or limited speech development, seizures, and 
hypotonia (Sykut-Cegielska et al., 2004; Caldeira Araújo et al., 
2005). Moreover, other genes were found to be repressed by MeCP2, 
such as myocyte enhancer factor 2C (Mef2c) and ataxin 2 bind-
ing protein 1 (A2bp1). A2BP1 regulates the splicing of neuronal 
genes and its disruption seems to be involved in mental retarda-
tion, epilepsy and autism susceptibility (Chahrour et al., 2008). 
Finally, proteomic analysis of the cerebellum by the same authors 
showed that several molecules involved in the transmission of nerve 
impulse, dendrite development and neuroblast proliferation are 
upregulated in mice overexpressing MeCP2 (Ben-Shachar et al., 
2009). Thus, despite the initial difficulties to find direct targets of 
MeCP2, the data obtained more recently using different RS animal 
models provide strong evidences that MeCP2 is involved in the 
regulation of genes crucial for the proper formation of neuronal 
circuits and synaptic   plasticity. Importantly, for some of the genes 
target of MeCP2 there are   evidences that their expression is mis-
regulated in other neurological diseases associated with mental 
retardation further indicating that they are fundamental for normal 
brain functions.
of MeCP2 (Collins et al., 2004). More recently we tested synaptic 
plasticity in the S1 cortex of 8 weeks old MeCP2-KO mice. Field 
potential recordings from layer II–III in response to white matter-
layer VI theta-burst stimulation revealed that in MeCP2Jae-KO male 
animals the response amplitude returned to baseline levels within 
45 min, showing that the expression of LTP is severely impaired 
in the cerebral cortex of these mutants (Lonetti et al., 2010). These 
data are in agreement with another study indicating that cortical 
LTP defects manifest only in older mutants and, importantly, after 
the appearance of deficits in excitatory synaptic transmission in 
younger, 2- to 3-week-old, MeCP2-null mice (Dani and Nelson, 
2009). Interestingly, truncated Mecp2308 male mice showed a similar 
reduction of LTP tested in layer II–III of the M1 and S1 cortices 
(Moretti et al., 2006).
mecp2 target geneS in neuronal cellS
Despite significant advances in our understanding of the abnor-
malities in synaptic connectivity produced by MeCP2 mutation, 
the precise molecular causes are still far from being understood. 
MeCP2 protein shows a methyl-CpG binding domain (MBD), 
through that it can bind methylated-CpG islands on genomic 
DNA, and a transcription repressor domain (TRD), that allows 
the interaction with co-repressors Sin3 and histone deacetylases 
(HDACs) 1 and 2. When assembled in such molecular complex, 
MeCP2 is able to induce epigenetic modifications of chromatin 
structure leading to the silencing of downstream genes. Although 
MeCP2 has been widely considered a general inhibitor of tran-
scription for years, a recent study has indicated that MeCP2 may 
also act as a gene activator in the brain through its association with 
CREB1, a major transcription factor that is crucially involved in 
activity-dependent modifications of synapses. MeCP2 gene activa-
tion function has been revealed by comparing results of genomic 
analyses conducted in the hypothalamus and in the cerebellum 
of WT mice and MeCP2 mutants (Chahrour et al., 2008; Ben-
Shachar et al., 2009). Importantly, Chahrour et al. (2008) showed 
that MeCP2 may bind directly to the promoter region of Creb1, a 
strong indication that CREB1 might represent one of the activated 
MeCP2 target.
An important discovery in RS research was the demonstration 
that MeCP2 regulates the expression of brain-derived neurotrophic 
factor (bdnf) in neurons (Chen et al., 2003; Martinowich et al., 2003). 
BDNF is a neurotrophin crucially involved both in the formation 
of synaptic circuits during brain development (Huang et al., 1999) 
and in adult synaptic plasticity (Zakharenko et al., 2003; Monteggia 
et al., 2004). The loss of MeCP2 in mice leads to the misregulation 
of BDNF expression, an alteration with important consequences 
on the disease’s symptoms. Indeed, symptomatic MeCP2-KO male 
mice show decreased levels of BDNF in different brain areas (Chang 
et al., 2006; Chahrour et al., 2008; Lonetti et al., 2010). By crossing 
MeCP2 heterozygous female mutants with transgenic mice overex-
pressing bdnf resulted in MeCP2 mutant male mice with ameliorated 
symptoms, at both cellular and behavioral level (Chang et al., 2006). 
Thus far, whether the action of MeCP2 on bdnf gene expression is 
direct or whether is an indirect effect remains a matter of discussion. 
The original in vitro experiments have indicated that MeCP2 acts 
as a repressor of bdnf by binding to its promoter III (Chen et al., 
2003; Martinowich et al., 2003). Moreover, these studies showed that Frontiers in Synaptic Neuroscience  www.frontiersin.org  August 2010  | Volume 2  | Article 28  |  6
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shown using mass spectrometry that human MeCP2 contains a 
phosphorylation site at Serine 80 (S80) that is also present both in 
mouse and rat proteins (Tao et al., 2009). Moreover, the analysis 
of brain extracts from epileptic mice revealed that multiple amino 
acid residues (S80, S399, T148/S149, S164, S229, S421, S424) in 
MeCP2 protein can be phosphorylated in mice after kainic acid-
based seizure induction while only two sites, S80 and S399, were 
found phosphorylated in control mouse brains.
The different pattern of MeCP2 phosphorylation suggests that 
the function of this gene may be finely tuned through dynamic 
covalent modifications induced by external stimuli. Further sup-
port for this idea comes from the results of experiments showing 
that phosphorylation of MeCP2 at S80 and S421 is modulated in 
different directions by neuronal activity, probably reflecting diverse 
activity-dependent pathwayS underlying  
mecp2 functionS
Importantly, it has been recently disclosed a role of MeCP2 in 
the modulation of activity-dependent gene regulation in neurons 
(Chen et al., 2003) indicating that MeCP2 can be directly engaged 
in the molecular processes underlying dynamic changes of syn-
apses in the brain. Membrane depolarization induced by KCl appli-
cation on cortical neuronal cultures leads to the phosphorylation 
of MeCP2 that correlates with increased rates of transcription of 
bdnf (Chen et al., 2003) (Figure 1A). Indeed, Ca2+ influx in neurons 
produces covalent modifications on specific amino acid residues of 
the MeCP2 protein – e.g., S80 and S421 – (Chen et al., 2003; Zhou 
et al., 2006; Chao and Zoghbi, 2009) that modulate its binding 
affinity to the DNA in response to neuronal activity. It has been 
FiGure 1 | Activity-dependent regulation of MeCP2 expression and 
function. (A) MeCP2 binding to the promoter region is regulated by its 
phosphorylation. Left: under basal conditions, MeCP2 is phosphorylated at S80 
site. Right: neuronal activity (e.g., through NMDA glutamate receptors and 
CaMKII activation) is associated with decreased phospho-S80 and increased 
levels of phospho-S421 MeCP2. (B) Expression of MeCP2 is negatively 
regulated by miR132 at the translational level. Left: MeCP2 overexpression, as 
well as blockade of miR132 repression increases BDNF III transcript levels. 
Right: Forskolin and KCl induce CREB phosphorylation that binds to the miR132 
promoter. Increased levels of miR132 reduce MeCP2 expression. Although this 
model may induce to hypothesize a reduction of BDNF expression, it was not 
shown by the original paper of Klein et al. (2007) whether the interplay between 
miR132 and MeCP2, after forskolin and KCl treatment, may affect this 
neurotrophin level.Frontiers in Synaptic Neuroscience  www.frontiersin.org  August 2010  | Volume 2  | Article 28  |  7
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normal firing rate of layer V pyramidal neurons in the S1 cortex indi-
cating that this genetic treatment is effective against synaptic altera-
tions in RS. Finally by achieving the proper expression of MeCP2 in 
null-mutant mice, behavioral, cellular, and synaptic symptoms were 
reversed even in adult animals (Giacometti et al., 2007; Guy et al., 
2007), implying that neurons are not permanently damaged by the 
absence of MeCP2. A remarkable set of experiments performed in 
the laboratory of Dr. Adrian Bird demonstrated that the disease 
in mice can be completely rescued, once the symptoms are fully 
expressed through the reintroduction of MeCP2 expression in cells 
(Guy et al., 2007). This work has taken advantage of a newly generated 
line of transgenic mice in which the endogenous MeCP2 is silenced 
through the insertion of a Stop cassette flanked by LoxP sequences 
(MeCP2LoxP-Stop). The induction of Cre expression obtained by 
tamoxifen (TM) injection in adult transgenic mice produced the 
deletion of the LoxP-Stop-LoxP region and allowed the expression 
of MeCP2. Acute daily TM-injection in MeCP2LoxP-Stop male mice 
at 3–4 weeks of age and the consequently reactivation of MeCP2 
expression prevented the development of symptoms and mutant 
mice survived without differences from WT mice. Moreover, the 
functional modifications. Brain extracts of mice that have under-
gone seizures showed a decrease of phospho-S80 MeCP2 levels 
while phospho-S421 MeCP2 was increased in these animals (Tao 
et al., 2009). While activity-dependent phosphorylation of S421 
reduced the binding of MeCP2 to methylated DNA (Chen et al., 
2003; Zhou et al., 2006), the phosphorylation of S80 seems to have 
an opposite effect (Figure 1A). Indeed MeCP2-S80A mutation 
decreases the binding level of MeCP2 at promoter region of target 
genes (i.e. Rab3d, Vamp3 and Igsf4b) indicating that phosphoryla-
tion at this site may be important for the modulation of transcrip-
tion (Tao et al., 2009). On the other hand, it has been shown that 
MeCP2 can be phosphorylated at S421 selectively in the nervous 
system. This covalent modification is induced by synaptic activity 
both in vitro, through applications of glutamate, NMDA or neu-
rotrophins on cultured hippocampal neurons, and in vivo in the 
parietal cortex by seizures induction and in the suprachiasmatic 
nucleus through sensory driven stimulations (Zhou et al., 2006). 
Moreover, MeCP2 phosphorylation on S421 can be mediated by the 
activation of the calcium-calmodulin kinase II (CaMKII), a protein 
kinase that is important for the molecular steps underlying the 
maintenance of later phases of synaptic plasticity as well as cogni-
tive functions (Zhou et al., 2006). Finally, the mutation of MeCP2 
at S421 in hippocampal organotypic slices blocks Ca2+-dependent 
bdnf transcription (Zhou et al., 2006).
More recently, it has been shown that MeCP2 expression can be 
regulated (Figure 1B) at the translational level by miR132, a micro-
RNA (miRNA) highly expressed in the brain, through the binding 
of the miRNA recognition element in the MeCP2 3′-UTR (Klein 
et al., 2007). Indeed, treatments with both forskolin and KCl induce 
the phosphorylation of CREB and miR132 expression, a molecular 
modification that results in the decrease of MeCP2 level. Moreover, 
while the introduction of miR132 into primary cortical neurons 
lowers the level of expression of MeCP2 protein, the block of miR132 
causes a very different effect by increasing the expression of BDNF 
(Figure 2B). In sum, these data lead to the conclusion that one of 
the main effect of the disruption of MeCP2 protein in the brain is 
a critical perturbation of activity-dependent gene transcription, a 
pathological process that may underlie the distinctive alterations of 
synaptic function and plasticity that are associated with RS.
reverSing Synaptic defectS in rett  
Syndrome modelS
Studies aiming at rescuing RS phenotype in animal models showed 
that nerve cells lacking MeCP2 can respond, at least partially, to 
genetic, pharmacological and behavioral treatments (see Table 3) 
further stimulating the research of efficient therapies (for a recent 
in-depth review of this topic see Cobb et al., 2010). Indeed, symp-
toms amelioration shown by RS mouse models was associated with 
structural and functional modifications of synapses. By crossing 
MeCP2Jae-KO  mice  with  transgenic  mice  overexpressing  BDNF 
protein  it  was  recently  obtained  a  novel  KO  male  mouse  line 
(CAGGsBDNF;Mecp2KO) in which the expression level of BDNF 
was increased and the appearance of RS symptoms was significantly 
delayed (Chang et al., 2006). These mice showed in comparison with 
MeCP2Jae-KO male mice a significantly longer lifespan, improve-
ments of locomotor functions and activity, as well as increased brain 
weight. Interestingly, increased BDNF levels were able to restore 
FiGure 2 | Structural effects of environmental enrichment on synaptic 
circuits of MeCP2 mutant mice. (A) MeCP2-KO and WT mice reared in 
standard conditions (ST) show similar excitatory and inhibitory synaptic density 
in the S1 cortex. Environmental enrichment (EE) leads to an increase of 
excitatory synapses and a loss of inhibitory synapses in WT male animals (blue 
pyramidal neurons). In KO male mice, EE produces an increase of excitatory 
contacts but no changes of inhibitory synapse density (cyan pyramidal neurons). 
(B) ST-MeCP2-KO mice show an increased number of inhibitory synapses on 
the soma and dendrites of Purkinje cells (PC) in the cerebellum compared to 
ST–WT. EE induce an increase of excitatory contacts in both genotypes. 
However, while EE increases the density of inhibitory synapses on both 
dendrites and soma in WT animals, it is able to increase only the density of 
inhibitory synapses on dendrites MeCP2-KO mice with no effect on inhibitory 
synapse density on the PC soma.Frontiers in Synaptic Neuroscience  www.frontiersin.org  August 2010  | Volume 2  | Article 28  |  8
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Table 3 | Synaptic effects of pharmacological and behavioral treatments in MeCP2 mutant mice.
intervention  Genetic reactivation of MeCP2  CAGGsBDNF;Mecp2KO  ee (Lonetti et al., 2010)  iGF1 treatment 
Synaptic parameter ( Guy et al., 2007)  (Chang et al., 2006)    (Tropea et al., 2009)
Excitatory synaptic density  ?  ?  +  +
Inhibitory synaptic density  ?  ?  − ?
Synaptic currents  ?  +*  ?  +**
Synaptic plasticity  +  ?  +  +***
Synaptic effects induced by genetic reactivation of MeCP2, genetic overexpression of BDNF , environmental enrichment (EE), and pharmacological treatments with 
IGF1 are indicated. See text for details.
? Not tested, + affected by the intervention, − not affected.
*Only firing rate of cortical layer V pyramidal neurons **only excitatory spontaneous EPSCs in the layer V of the cortex*** tested using ocular dominance 
plasticity.
features of immature animals when tested for ocular dominance 
plasticity induced by monocular deprivation. Importantly, this syn-
aptic phenotype was normalized in mutants that received IGF-1 
treatment (Tropea et al., 2009), a result further supporting the idea 
that activity-dependent synaptic abnormalities shown by MeCP2 
mutants may be reversed by an appropriate treatment.
Recently we asked whether environmental enrichment (EE), a 
behavioral treatment that is known to induce structural remodeling 
in the brain, was able to produce beneficial effects on the phenotypic 
features expressed by null MeCP2 mice (Lonetti et al., 2010). The 
correct formation of neural circuits requires experience-dependent 
stabilization and remodeling of synaptic connections. When reared 
in EE animals are placed in large groups in cages containing toys and 
running wheels enhancing and facilitating social interactions with 
other mice, as well as sensory-motor and cognitive stimulations. 
It has been previously shown that this housing condition exerts 
several beneficial effects on many mouse models of neurological 
disorders like Huntington, Parkinson, and Alzheimer disease at a 
behavioral, cellular, and molecular level (Nithianantharajah and 
Hannan, 2006). Moreover, this treatment is able to enhance syn-
apse formation and plasticity and to increase the production of 
BDNF, a neurotrophin that is strongly reduced in MeCP2-KO mice. 
Intriguingly, we have shown that rearing of MeCP2Jae-KO mice in 
enriched conditions from P10 rescued cortical LTP deficits shown 
by mutants reared in standard conditions (Lonetti et al., 2010). 
Moreover, using unbiased stereology applied to electron micros-
copy, we found that both in the III layer of the S1 cortex and in the 
molecular layer of the cerebellum EE is able to induce the growth of 
new excitatory synapses both in WT and KO male mice, indicating 
that nerve cells lacking MeCP2 may show structural remodeling 
of excitatory synapses in response to environmental stimulation 
(Figure 2). Finally, combined with the beneficial effects at the syn-
aptic level, we found that early intervention also increased the levels 
of BDNF expression in the cortex of MeCP2 mutants and amelio-
rated several behavioral features of RS (Lonetti et al., 2010).
activity-dependent defectS of inhibitory SynapSeS 
in mecp2-null brain
The employment of early EE allowed us also to disclose defects 
at GABAergic synapses produced by MeCP2 null mutation that 
were not clearly evident in mutant mice reared in ST conditions 
reactivation of MeCP2 expression by TM-injection in MeCP2LoxP-
Stop heterozygous female that showed typical neurological defects 
was able to revert the behavioral symptoms and rescued the abnor-
malities of LTP expression induced by theta-burst stimulation in the 
hippocampus. These data demonstrated that the absence of normal 
levels of MeCP2 during development does not irreversibly damage 
both neuronal function and the molecular machinery underlying 
synaptic circuit properties, and most importantly, that most of RS 
symptoms may be reversible (Guy et al., 2007).
Although genetic interventions have proven very promising in 
resolving, or at least ameliorating, neuropathological signs of RS 
in animal models, the application of such therapies in humans 
are not foreseen to be accessible in a near future. Thus, a primary 
goal of RS research is to focus toward the development of afford-
able non-genetic therapies aimed to resolve malfunctions in neu-
ral circuits. Intriguingly, a recent pharmacological treatment in 
MeCP2-KO mice with insulin-like growth factor 1 (IGF-1) pro-
duced very promising results both at the cellular and the behavioral 
level (Tropea et al., 2009). It has been previously demonstrated that 
IGF-1, a pleiotrophic growth factor that is able to cross the hema-
toencephalic barrier, has beneficial effect on cognition in aging 
animals (Markowska et al., 1998; Trejo et al., 2004). Moreover trans-
genic mice with IGF-1 deficiency show defects in hippocampal 
LTP and reduction of glutamatergic boutons (Trejo et al., 2007). 
Importantly, it was shown that prolonged systemic administration 
of IGF-1 is able to rescue these synaptic alterations (Trejo et al., 
2007). Tropea et al. (2009) showed that the early (2 weeks after 
birth) intraperitoneal injection of IGF-1 improved survival, loco-
motory activity, breathing irregularity, and cardiac arrhythmias in 
MeCP2Jae-KO male mice Tropea et al. (2009). Together with these 
behavioral and systemic improvements, IGF-1 was able to partially 
restore brain weight deficits in MeCP2 mutants and was also effec-
tive on synapses. Indeed, the motor cortex of KO-mice treated with 
IGF-1 showed an augmented level of expression of the postsynaptic 
protein PSD-95 compared with untreated MeCP2-KO animals. This 
result was paralleled by an increase in dendritic spine density and 
in spontaneous EPSCs frequency of layer V pyramidal neurons of 
the M1 cortex. Moreover, the administration of IGF-1 was effective 
in rescuing synaptic defects in heterozygous female (Tropea et al., 
2009). These authors found that the neural circuits of the visual cor-
tex of adult MeCP2Jae heterozygous females showed typical   synaptic Frontiers in Synaptic Neuroscience  www.frontiersin.org  August 2010  | Volume 2  | Article 28  |  9
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Widespread changes in dendritic and 
synapses in MeCP2-KO mice (Lonetti et al., 2010). Therefore, it is 
clear that a detailed brain map of the anatomical and physiological 
alterations in synaptic plasticity is needed to understand how neu-
ronal circuits are ultimately compromised in RS. Moreover, testing 
the temporal progression of the neural dysfunctions produced by 
MeCP2 mutation will contribute to an earlier identification of RS 
thus providing useful indications to model efficient protocols for 
future therapies. Although an apparently normal early development 
had initially been considered as one of the criteria for RS, several 
retrospective studies indicated the disorder to manifest during the 
first year of life (e.g., Kerr and Witt Engerström, 2001). While altera-
tions have been reported in dendritic spine morphology of MeCP2 
mutant mice at early ages (Belichenko et al., 2009b; our unpublished 
observations), little is known about the structure and function of 
dendritic spines and synapses in very young mutants. Knowledge 
about the exact mechanisms of synapse formation, stabilization, or 
pruning that are affected by MeCP2 mutation at early stages of the 
disease could reveal the primary deficits underlying the phenotype 
of MeCP2 mutants. Intriguingly, we found that early EE improves 
several phenotypes of female MeCP2+/− and male MeCP2Jae-KO 
mice (Lonetti et al., 2010). By contrast, late onset EE has more subtle 
effects (Kondo et al., 2008; Nag et al., 2009) suggesting that early 
EE could be particularly valuable to normalize the initial pathologi-
cal signs occurring during early postnatal development. Thus, it is 
reasonable to envision that early intervention after early diagnosis 
might achieve the best results in RS patients. Finally, the results 
showing that the treatments used so far produced only partial recov-
ery of the symptoms indicate that there are unknown neuronal 
defects that are particularly resilient. Thus, future studies focused 
on the characteristics of population-specific function of MeCP2 in 
neurons will prevent possible confounding dilution effects due to 
the extreme neuronal heterogeneity existing in the brain, and will 
provide new knowledge helping to identify the molecular bases of 
the clinical problems.
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(Figure 2). MeCP2 mutants in ST conditions display WT-like 
numbers of GABA-positive inhibitory synapses in the S1 area of 
the cortex. Whereas S1 cortices of WT animals showed a robust 
reduction in the density of GABAergic axo-dendritic contacts in EE 
conditions, these contacts were unchanged in MeCP2Jae-KO mice 
after EE (Lonetti et al., 2010). Intriguingly, no change was detected 
in the number of axo-somatic inhibitory synapses between WT and 
KO animals in both ST and EE rearing conditions.
Thus, in WT animals EE results in an increased ratio between 
excitatory and inhibitory synapses due to a new growth of excitatory 
synapses and a parallel retraction of inhibitory synapses (see also 
Nithianantharajah and Hannan, 2006; Alvarez and Sabatini, 2007; 
Sale et al., 2007). This effect was present also in the cortex of EE 
MeCP2-KO mice, but differently from normal animals it derived 
exclusively from an increase of excitatory synapses with no changes 
in inhibitory synapse number. These results thus lead to the interest-
ing conclusion that structural synaptic plasticity in the S1 cortex of 
8 weeks old MeCP2-KO mice is normal in excitatory circuits whereas 
is altered in inhibitory circuits. Furthermore, we found that inhibi-
tory circuits in the cerebellum responded differently to EE (Lonetti 
et al., 2010). Indeed, both in WT and in MeCP2-KO animals stellate 
cells-Purkinje cells GABAergic synapse density was strongly increased 
under EE conditions. However, in the same region we found that 
perisomatic synapse number between basket cells and Purkinje cells is 
increased in EE WT mice but not in EE KO mice, thus indicating that 
MeCP2 deletion may produce cell-specific impairments in structural 
plasticity of GABAergic synapses in the cerebellum. Altogether, these 
data strongly suggest that, in addition to alterations in excitatory 
connectivity, cortical interneurons could be important substrates of 
the phenotypic alterations of MeCP2 mutants and that the integrity 
of GABAergic circuits is affected in RS.
concluSionS
The wide range of the phenotypes shown both by patients with 
MeCP2 mutations and murine models carrying alterations in MeCP2 
expression and function indicated that behavioral abnormalities stem 
from MeCP2 dysfunction taking place in specific neuronal subpopu-
lations. Indeed, genetic manipulations that produced the removal 
of MeCP2 functions in selected brain areas (e.g., hypothalamus) 
or neuronal types (e.g., serotonergic, dopaminergic, and noradren-
ergic) caused specific behavioral, cellular, and molecular changes 
(Fyffe et al., 2008; Samaco et al., 2009). Similarly, several evidences 
have indicated that loss of MeCP2 may affect synaptic connectivity 
with variable degrees of intensity in specific brain areas and neural 
circuits. For example, the loss of MeCP2 seems to affect structural 
plasticity of inhibitory synapses induced by behavioral stimulation 
only within selected populations of interneurons both in the cerebral 
and the cerebellar cortex. In contrast, the capabilities to respond with 
structural changes to external stimulation are preserved at excitatory Frontiers in Synaptic Neuroscience  www.frontiersin.org  August 2010  | Volume 2  | Article 28  |  10
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